Cardiff Oncology
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1999-01-01
- Employees
- 31
- Market Cap
- -
- Introduction
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
- Conditions
- CRCMetastatic Colorectal CancerKRAS/NRAS Mutation
- Interventions
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Cardiff Oncology
- Target Recruit Count
- 113
- Registration Number
- NCT06106308
- Locations
- 🇺🇸
Mayo Clinic - Arizona, Phoenix, Arizona, United States
🇺🇸The University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸St. Bernards Medical Center, Jonesboro, Arkansas, United States
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation
- Conditions
- Metastatic Colorectal CancerColorectal Cancer
- Interventions
- First Posted Date
- 2022-10-25
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Cardiff Oncology
- Target Recruit Count
- 23
- Registration Number
- NCT05593328
- Locations
- 🇺🇸
Mayo Clinic in Arizona - Phoenix Campus, Phoenix, Arizona, United States
🇺🇸Central Arkansas Radiation Therapy Institute - Cancer Center, Little Rock, Arkansas, United States
🇺🇸Pacific Cancer Medical Center, Anaheim, California, United States
Onvansertib in Combination with Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants with Metastatic Pancreatic Ductal Adenocarcinoma
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Cardiff Oncology
- Target Recruit Count
- 43
- Registration Number
- NCT04752696
- Locations
- 🇺🇸
Mayo Clinic Phoenix, Phoenix, Arizona, United States
🇺🇸Mayo Clinic Jacksonville, Jacksonville, Florida, United States
🇺🇸University of Kansas Medical Center, Westwood, Kansas, United States
Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer
- Conditions
- Metastatic Colorectal CancerKRAS Gene Mutation
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Cardiff Oncology
- Registration Number
- NCT04446793
Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation
- Conditions
- Metastatic Colorectal CancerKRAS Gene Mutation
- Interventions
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Cardiff Oncology
- Target Recruit Count
- 68
- Registration Number
- NCT03829410
- Locations
- 🇺🇸
Mayo Clinic Cancer Center, Phoenix, Arizona, United States
🇺🇸CARTI Cancer Center, Little Rock, Arkansas, United States
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- First Posted Date
- 2018-01-29
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Cardiff Oncology
- Target Recruit Count
- 72
- Registration Number
- NCT03414034
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2017-10-06
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Cardiff Oncology
- Target Recruit Count
- 72
- Registration Number
- NCT03303339
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸Yale University, New Haven, Connecticut, United States
🇺🇸University of Kansas Cancer Center, Westwood, Kansas, United States